A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances

por Pepose, Jay, Brigell, Mitchell, Lazar, Eliot, Heisel, Curtis, Yousif, Jonah, Rahmani, Kavon, Kolli, Ajay, Hwang, Min, Mitrano, Cara, Lazar, Audrey, Charizanis, Konstantinos, Sooch, Mina, McDonald, Marguerite
Publicado 2022

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

por Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Publicado 2013

Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial

por Pepose, Jay S, Hartman, Paul J, DuBiner, Harvey B, Abrams, Marc A, Smyth-Medina, Robert J, Moroi, Sayoko E, Meyer, Alan R, Sooch, Mina P, Jaber, Reda M, Charizanis, Konstantinos, Klapman, Seth A, Amin, Arin T, Yousif, Jonah E, Lazar, Eliot S, Karpecki, Paul M, Slonim, Charles B, McDonald, Marguerite B
Publicado 2021

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

por Rodrigueza, Wendi V., Woolliscroft, Michael J., Ebrahim, Abdul-Shukkur, Forgey, Robert, McGovren, Patrick J., Endert, Gerold, Wagner, Andreas, Holewa, Danielle, Aboukameel, Amro, Gill, Richard D., Bisgaier, Charles L., Messmann, Richard A., Whitehead, Christopher E., Izbicka, Elzbieta, Streeper, Robert, Wick, Michael C., Stiegler, Gabriela, Stein, C. A., Monsma, David, Webb, Craig, Sooch, Mina P., Panzner, Steffen, Mohammad, Ramzi, Goodwin, Neal C., Al-Katib, Ayad
Publicado 2014